文献速递关节外科

全关节置换术后GLP-1受体激动剂无中期获益:系统综述

No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty: A Systematic Review.
PubMed 文献 · J Bone Joint Surg Am · 2026-04-01

该系统综述评估GLP-1受体激动剂对髋或膝关节置换患者医疗并发症、植入物失败率及医疗费用的影响,纳入8项回顾性研究共22,611例使用者与77,810例对照。结果显示GLP-1受体激动剂与术后90天内再入院率和费用降低相关,但假体周围感染预防效果不一,2年随访无一致临床优势。证据等级为治疗性III级。

要点

  • GLP-1受体激动剂与术后90天内再入院率降低29%至47%相关。
  • 假体周围感染率降低30%至44%见于5项研究,但3项研究无显著差异。
  • 2年随访未观察到一致的临床优势。

核心结论

  • GLP-1受体激动剂治疗与全关节置换术后90天内再入院率和费用降低相关,但假体周围感染预防效果不一,2年随访无一致临床优势。

研究设计与样本

  • 系统综述检索PubMed、Embase、Web of Science、Cochrane图书馆、WHO ICTRP和UK Clinical Trials Gateway,限数据库建库至2025年3月31日。
  • 纳入随机对照试验或队列研究,对象为接受全关节置换且使用任何剂量或疗程GLP-1受体激动剂的成人(≥18岁)。
  • 采用Cochrane偏倚风险工具和ROBINS-I评估偏倚风险,因研究设计异质性大采用定性合成。

主要发现

  • 共纳入8项回顾性研究,包括22,611例GLP-1受体激动剂使用者和77,810例对照,患者平均年龄56至64岁。
  • 3项研究报告GLP-1受体激动剂使用者术后90天内再入院率显著降低29%至47%。
  • 5项研究显示GLP-1受体激动剂使用与假体周围感染率显著降低30%至44%相关,而3项研究未发现显著差异。
  • 多项研究显示GLP-1受体激动剂治疗与住院时间缩短和90天费用降低相关。
  • 医疗并发症结果不一:部分研究报告血管和肺部事件增加,另一些观察到脓毒症和低血糖事件减少。

关键数值与推荐

  • 再入院率:3项研究报告术后90天内显著降低29%至47%。
  • 假体周围感染率:5项研究报告显著降低30%至44%,3项研究无显著差异。
  • 证据等级:治疗性III级。

临床怎么用

  • 对于接受全关节置换的糖尿病患者,GLP-1受体激动剂可能减少90天内再入院和费用,但需权衡并发症风险。
  • 假体周围感染预防获益不一致,不应仅基于此常规推荐GLP-1受体激动剂。
  • 中期(2年)随访无一致临床优势,需个体化决策。

局限性

  • 仅纳入回顾性研究,存在选择偏倚和混杂可能。
  • 研究设计异质性大,仅能进行定性合成。
  • 未报告随机对照试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this systematic review was to evaluate the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on medical complications, implant failure rates, and health-care-related costs in patients undergoing hip or knee arthroplasty. METHODS: A comprehensive search of electronic databases, including PubMed, Embase, Web of Science, the Cochrane Library, the World Health Organization International Clinical Trials Registry Platform (ICTRP), and the UK Clinical Trials Gateway, was conducted and was limited to studies from database inception to March 31, 2025. Inclusion criteria comprised randomized controlled trials or cohort studies involving adults (≥18 years old) undergoing total joint arthroplasty (TJA) while receiving a GLP-1 RA treatment of any dosage or duration. The risk of bias was assessed using the Cochrane risk-of-bias tool and ROBINS-I (Risk Of Bias In Non-Randomized Studies - of Interventions) assessment. Due to substantial heterogeneity in the study designs, a qualitative synthesis approach was employed. RESULTS: Eight retrospective studies met the inclusion criteria, encompassing 22,611 GLP-1 RA users and 77,810 controls. The mean patient age ranged from 56 to 64 years. Hospital readmission rates showed the most consistently favorable results among GLP-1 RA users, with 3 studies reporting significant reductions of 29% to 47% during the 90-day postoperative period. Five studies demonstrated that GLP-1 RA use was associated with significant reductions, ranging from 30% to 44%, in periprosthetic joint infection (PJI) rates, whereas 3 studies found no significant differences. Hospital resource utilization favored GLP-1 RA therapy, with several studies demonstrating shorter hospital stays and lower 90-day costs. Medical complications yielded variable results: some studies reported increased vascular and pulmonary events among GLP-1 RA users, whereas others observed reduced sepsis and hypoglycemic events in those patients. CONCLUSIONS: GLP-1 RA therapy was associated with reduced hospital readmissions and decreased hospital costs within 90 days postoperatively, although its benefits for PJI prevention showed mixed results, with some studies demonstrating significant reductions in PJI while others showed no difference. No consistent clinical advantages were observed at the 2-year follow-up. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Leggieri F, van Laarhoven SN, León Muñoz VJ, et al. No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty: A Systematic Review. J Bone Joint Surg Am. 2026. PMID: 41921052. doi:10.2106/JBJS.25.00879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。